A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
To establish the maximum tolerated dose (MTD) of oral afatinib (BIBW2992) given in
combination with gemcitabine or docetaxel in patients with relapsed or refractory tumors.
To assess the safety of the combination. To investigate the PK characteristics of docetaxel
or gemcitabine and of oral afatinib (BIBW2992) in the tested treatment schedule. To assess
antitumor activity.